18F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: Do we need additional tracers for clinical purposes?

Thomas C. Kwee; Saeid Gholami; Thomas J. Werner; Domenico Rubello; Abass Alavi; Poul F. Høilund-Carlsen

doi:10.1097/MNM.0000000000000478

¹⁸F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: Do we need additional tracers for clinical purposes?

Thomas C. Kwee
, Saeid Gholami
, Thomas J. Werner
, Domenico Rubello
, Abass Alavi
, Poul F. Høilund-Carlsen^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	333-337
Number of pages	5
Journal	Nuclear Medicine Communications
Volume	37
Issue number	4
DOIs	https://doi.org/10.1097/MNM.0000000000000478
Publication status	Published - 2016

Access to Document

10.1097/MNM.0000000000000478

1Final published version, 133 KBLicence: Taverne

Cite this

@article{de8ad113e4ff44eeb9f811763b394ca1,

title = "18F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: Do we need additional tracers for clinical purposes?",

author = "Kwee, \{Thomas C.\} and Saeid Gholami and Werner, \{Thomas J.\} and Domenico Rubello and Abass Alavi and H{\o}ilund-Carlsen, \{Poul F.\}",

year = "2016",

doi = "10.1097/MNM.0000000000000478",

language = "English",

volume = "37",

pages = "333--337",

journal = "Nuclear Medicine Communications",

issn = "0143-3636",

publisher = "Wolters Kluwer Health",

number = "4",

}

¹⁸F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: Do we need additional tracers for clinical purposes? / Kwee, Thomas C.; Gholami, Saeid; Werner, Thomas J. et al.
In: Nuclear Medicine Communications, Vol. 37, No. 4, 2016, p. 333-337.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - 18F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains

T2 - Do we need additional tracers for clinical purposes?

AU - Kwee, Thomas C.

AU - Gholami, Saeid

AU - Werner, Thomas J.

AU - Rubello, Domenico

AU - Alavi, Abass

AU - Høilund-Carlsen, Poul F.

PY - 2016

Y1 - 2016

UR - https://www.scopus.com/pages/publications/84954550567

U2 - 10.1097/MNM.0000000000000478

DO - 10.1097/MNM.0000000000000478

M3 - Editorial

C2 - 26796033

AN - SCOPUS:84954550567

SN - 0143-3636

VL - 37

SP - 333

EP - 337

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

IS - 4

ER -

18F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: Do we need additional tracers for clinical purposes?

Access to Document

Other files and links

Cite this

¹⁸F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: Do we need additional tracers for clinical purposes?